132 related articles for article (PubMed ID: 38604261)
1. Discovery and characterization of novel ATP citrate lyase inhibitors from Acanthopanax senticosus (Rupr. & Maxim.) Harms.
Wang P; Guo X; Hou T; Luo F; Li M; Wang X; Zhang J; Wang J; Wang C; Liang X
Fitoterapia; 2024 Jun; 175():105956. PubMed ID: 38604261
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Flavonoids as Novel Inhibitors of ATP Citrate Lyase: Structure-Activity Relationship and Inhibition Profiles.
Wang P; Hou T; Xu F; Luo F; Zhou H; Liu F; Xie X; Liu Y; Wang J; Guo Z; Liang X
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142671
[TBL] [Abstract][Full Text] [Related]
3. High-throughput ultra high performance liquid chromatography combined with mass spectrometry approach for the rapid analysis and characterization of multiple constituents of the fruit of Acanthopanax senticosus (Rupr. et Maxim.) Harms.
Han Y; Zhang A; Sun H; Zhang Y; Meng X; Yan G; Liu L; Wang X
J Sep Sci; 2017 May; 40(10):2178-2187. PubMed ID: 28371133
[TBL] [Abstract][Full Text] [Related]
4. An allosteric mechanism for potent inhibition of human ATP-citrate lyase.
Wei J; Leit S; Kuai J; Therrien E; Rafi S; Harwood HJ; DeLaBarre B; Tong L
Nature; 2019 Apr; 568(7753):566-570. PubMed ID: 30944472
[TBL] [Abstract][Full Text] [Related]
5. Five new sesquiterpenoids from the fruits of Acanthopanax senticosus (Rupr. & Maxim.) Harms.
Zhang ML; Sun YP; Liu Y; Pan J; Guan W; Li XM; Wang SY; Naseem A; Yang BY; Kuang HX
Fitoterapia; 2021 Mar; 149():104827. PubMed ID: 33429023
[TBL] [Abstract][Full Text] [Related]
6. Discovery and characterization of novel ATP citrate lyase inhibitors from natural products by a luminescence-based assay.
Wang P; Peng X; Hou T; Xu F; Zhou H; Yu Y; Qiu M; Liu Y; Zhao Y; Guo Z; Wang J; Liang X
Chem Biol Interact; 2022 Nov; 367():110199. PubMed ID: 36174740
[TBL] [Abstract][Full Text] [Related]
7. Identification of isomeric dicaffeoylquinic acids from Eleutherococcus senticosus using HPLC-ESI/TOF/MS and 1H-NMR methods.
Tolonen A; Joutsamo T; Mattlla S; Kämäräinen T; Jalonen J
Phytochem Anal; 2002; 13(6):316-28. PubMed ID: 12494749
[TBL] [Abstract][Full Text] [Related]
8. ATP citrate lyase (ACLY) inhibitors: An anti-cancer strategy at the crossroads of glucose and lipid metabolism.
Granchi C
Eur J Med Chem; 2018 Sep; 157():1276-1291. PubMed ID: 30195238
[TBL] [Abstract][Full Text] [Related]
9. ATP-citrate lyase: genetics, molecular biology and therapeutic target for dyslipidemia.
Burke AC; Huff MW
Curr Opin Lipidol; 2017 Apr; 28(2):193-200. PubMed ID: 28059952
[TBL] [Abstract][Full Text] [Related]
10. [Advances in caffeoylquinic acid research].
Zhao Y; Zhao J; Li XP; Zhou CX; Sun HD; Hao XJ; Xiao PG
Zhongguo Zhong Yao Za Zhi; 2006 Jun; 31(11):869-74. PubMed ID: 17048619
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous determination of protocatechuic acid, syringin, chlorogenic acid, caffeic acid, liriodendrin and isofraxidin in Acanthopanax senticosus Harms by HPLC-DAD.
Li Q; Jia Y; Xu L; Wang X; Shen Z; Liu Y; Bi K
Biol Pharm Bull; 2006 Mar; 29(3):532-4. PubMed ID: 16508160
[TBL] [Abstract][Full Text] [Related]
12. A new 3,4-seco-lupane-type triterpenoid from the pulp of Acanthopanax senticosus (Rupr. et Maxim) Harms.
Yan ZW; Liu JP; Lu D; Groundwater P; He CY; Li PY
Nat Prod Res; 2010 Oct; 24(16):1523-7. PubMed ID: 20835953
[TBL] [Abstract][Full Text] [Related]
13. ATP citrate lyase (ACLY): a promising target for cancer prevention and treatment.
Khwairakpam AD; Shyamananda MS; Sailo BL; Rathnakaram SR; Padmavathi G; Kotoky J; Kunnumakkara AB
Curr Drug Targets; 2015; 16(2):156-63. PubMed ID: 25537655
[TBL] [Abstract][Full Text] [Related]
14. ATP citrate lyase inhibitor triggers endoplasmic reticulum stress to induce hepatocellular carcinoma cell apoptosis via p-eIF2α/ATF4/CHOP axis.
Zheng Y; Zhou Q; Zhao C; Li J; Yu Z; Zhu Q
J Cell Mol Med; 2021 Feb; 25(3):1468-1479. PubMed ID: 33393219
[TBL] [Abstract][Full Text] [Related]
15. Identification of lignans as ATP citrate lyase (ACLY) inhibitors from the roots of
Li JL; Jiang JY; Gu SS; Zhang L; Sun Y; Wang XH; Li DY; Chen ZY; Jiang SS; Zhu WZ; Jiang HW; Zhang HJ
Nat Prod Res; 2024 May; 38(10):1719-1726. PubMed ID: 37265118
[TBL] [Abstract][Full Text] [Related]
16. Effects of Acanthopanax senticosus (Rupr. & Maxim.) Harms on cerebral ischemia-reperfusion injury revealed by metabolomics and transcriptomics.
Chen RH; Du WD; Wang Q; Li ZF; Wang DX; Yang SL; Feng YL
J Ethnopharmacol; 2021 Jan; 264():113212. PubMed ID: 32768643
[TBL] [Abstract][Full Text] [Related]
17. ATP-citrate lyase (ACLY) inhibitors as therapeutic agents: a patenting perspective.
Granchi C
Expert Opin Ther Pat; 2022 Jul; 32(7):731-742. PubMed ID: 35436171
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a Novel Macrocyclic ATP Citrate Lyase Inhibitor.
Zang Y; Tai L; Hu Y; Wang Y; Sun H; Wen X; Yuan H; Dai L
J Chem Inf Model; 2022 Jun; 62(12):3123-3132. PubMed ID: 35679529
[TBL] [Abstract][Full Text] [Related]
19. Integrating serum pharmacochemistry and network pharmacology to explore the molecular mechanisms of Acanthopanax senticosus (Rupr. & Maxim.) Harms on attenuating doxorubicin-induced myocardial injury.
Zhang X; Zhang Q; Yu M; Zhang Y; He T; Qiu Z; Qiu Y; Wang W
J Ethnopharmacol; 2024 Jan; 319(Pt 3):117349. PubMed ID: 38380572
[TBL] [Abstract][Full Text] [Related]
20. A review of Acanthopanax senticosus (Rupr and Maxim.) harms: From ethnopharmacological use to modern application.
Jia A; Zhang Y; Gao H; Zhang Z; Zhang Y; Wang Z; Zhang J; Deng B; Qiu Z; Fu C
J Ethnopharmacol; 2021 Mar; 268():113586. PubMed ID: 33212178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
